A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT07589634 · RECRUITING
Trial details
- NCT number
- NCT07589634
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2027-12-31
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.